Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Conditions: Poliomyelitis; Diphtheria; Haemophilus Influenzae Type b; Tetanus; Acellular Pertussis; Hepatitis BInterventions: Biological: Infanrix hexa; Biological: Pediarix; Biological: ActHIB; Biological: Pentacel; Biological: Engerix-B; Biological: Infanrix; Biological: Hiberix; Biological: Prevnar13; Biological: RotarixSponsor: GlaxoSmithKlineActive, not recruiting - verified December 2014

http://clinicaltrials.gov/ct2/show/NCT02096263?lup_s=11%2F18%2F2014&lup_d=30

Source: ClinicalTrials.gov - March 21, 2014 Category: Research Source Type: clinical trials